SU1297865A1 - Method of treatment of patients ill with chronic non-specific ulcerative colitis - Google Patents
Method of treatment of patients ill with chronic non-specific ulcerative colitis Download PDFInfo
- Publication number
- SU1297865A1 SU1297865A1 SU843735811A SU3735811A SU1297865A1 SU 1297865 A1 SU1297865 A1 SU 1297865A1 SU 843735811 A SU843735811 A SU 843735811A SU 3735811 A SU3735811 A SU 3735811A SU 1297865 A1 SU1297865 A1 SU 1297865A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- treatment
- ulcerative colitis
- day
- chronic non
- days
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 title claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims description 6
- 206010009887 colitis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 240000007817 Olea europaea Species 0.000 claims 1
- 230000008092 positive effect Effects 0.000 claims 1
- 239000004006 olive oil Substances 0.000 abstract description 5
- 235000008390 olive oil Nutrition 0.000 abstract description 5
- 102000014150 Interferons Human genes 0.000 abstract description 4
- 108010050904 Interferons Proteins 0.000 abstract description 4
- 229940079322 interferon Drugs 0.000 abstract description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 230000000544 hyperemic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение сокращает сроки Лечени . Дл этого ректально ввод т ли- немент, состо щий из интерферона, ви- нилина и оливкового масла, в общеприн тых дозах в течение 25-30 дней. (Л СThe invention shortens the treatment time. For this purpose, a rectum consisting of interferon, vinilin and olive oil is administered rectally in standard doses for 25-30 days. (Ls
Description
1l1l
Изобретение относитс к медии.ине и касаетс способов лечени хронического неспецифического звенного коли та.The invention relates to media. And relates to methods of treating chronic nonspecific ulcer colitis.
Целью изобретени вл етс сокращение сроков лечени больных хроническим неспецифическим звенным колитом за счет ректального введени линемента, состо щего из интерферона винилина и оливкового масла, в общеприн тых дозах в течение 25-30 дней. Пример). Больной Г., 29 л., диагноз: хронический неспецифический звенный колит установлен на основании клинических, ректоскопических и рентгенологических данных,. Поступил на 17-й день обострени в период выраженной активности процесса - стул до 40 раз в сутки с кровью и слизью, интоксикаци , лихорадка, потер массы тела на 12 кг. При ректоромано- скопии до начала лечени обнаружено, что слизиста дистального отдела Кишки на прот жении 20 см резко отечна, гиперемирована,кровоточит5 видны множественные эрозии. Начато лечение путем ректального введени линемента, состо щего из интерферона, винилина, оливкового масла, в общеприн тых дозах , С А-го дн лечени исчезли интоксикаци и лихорадка, с 1Д-го дн - оформленный стул 2-4 раза в сутки с небольшим количеством патологических примесей. На 20-й и 24-й дни лечени при ректороманоскопии установлено, что признаки активности процесса еще сох1:ан ютс : отек, гипереми , контактна кровоточивость, единичные эрозии. На 27-й день лечени данные эндоскопического обследовани свидетельствовали об отчетливой положительной динамике и исчезновении симптомов активности болезни: контактной кровоточивости, эрозии, с этого времени прекращено лечение линементом. Наступила стойка ремисси , продолжающа с до сих пор, IThe aim of the invention is to reduce the time of treatment of patients with chronic nonspecific ulcerative colitis due to rectal injection of a membrane consisting of interferon-vinylin and olive oil, in standard doses for 25-30 days. Example). Patient G., 29 years old, diagnosis: chronic nonspecific ulcerative colitis is established on the basis of clinical, rectoscopic and radiological data. Entered on the 17th day of exacerbation during the period of pronounced activity of the process - stools up to 40 times per day with blood and mucus, intoxication, fever, body weight loss by 12 kg. During rectoromanoscopy, prior to treatment, it was found that the mucous of the distal intestine over the course of 20 cm was sharply edematous, hyperemic, bleeding5, multiple erosions are visible. Treatment was started by rectal injection of a line consisting of interferon, vinylin, olive oil, in conventional doses, intoxication and fever disappeared from the same day of treatment, and from 1D to the end - a decorated chair 2-4 times a day with a small amount pathological impurities. On the 20th and 24th days of treatment with rectoromanoscopy, it was established that the signs of the activity of the process still remain: they are: edema, hyperemia, contact bleeding, isolated erosion. On the 27th day of treatment, the endoscopic examination data showed a clear positive trend and disappearance of the symptoms of the disease activity: contact bleeding, erosion, and since that time the treatment with the help of the thrill was stopped. There is a remission stance, continuing with until now, I
П р и м е р 2. Больной Д., 27 л., страдает хроническим неспецифическим звенным колитом в течение п ти л. Неоднократно лечилс преднизолоном и сульфасалазином без эффекта. Поступил в период обострени - стул 6- 8 раз в сутки с большим количеством крови и слизи, боли в животе. Ректо- романоскопи до лечени : на прот жении 20 см слизиста кишки рко гиперемирована , контактна кровоточивостPRI mme R 2. Patient D., 27 years old, suffers from chronic nonspecific ulcerative colitis for five liters. Repeatedly treated with prednisone and sulfasalazine without effect. He entered the period of exacerbation - stools 6-8 times a day with lots of blood and mucus, pain in the abdomen. Recto-Romanoscopy before treatment: throughout 20 cm of the intestinal mucosa is brightly hyperemic, contact bleeding
5five
00
5five
00
5five
00
5five
00
5five
, лилчст Н1М I гм, 1,1ча-- то лечение riyrf M ректлпьнсц с рг} допи ли гемйнта, содержащего интерферон, винилин, оливковое масло. На 18-й день терапии стул нормализовалс ,количество патолог ических примесей уменьщилось, исчезли боли в животе. При эндоскопии на20-й день лечени прослеживаетс незначительна положительна динамика - меньше кровоточивость , начинающа с эпителизаци зв, а на день терапии - небольша гипереми , легка контактна кровоточивость ,, полна эпителизаци зв, зернистость слизистой оболочки, т.е. минимальные признаки активности патологического процесса, что соответствует ремиссии. Лечение прекращено. Наступила стойка ремисси , продол жающа с по насто щее врем ., licht H1M I gm, 1.1 hours - then treatment riyrf M reklnbsts with rg} doped a hemynt containing interferon, vinylin, olive oil. On the 18th day of therapy, the stool returned to normal, the amount of pathological impurities decreased, and abdominal pain disappeared. During endoscopy, on the 20th day of treatment, there is a slight positive dynamics: less bleeding, starting with epithelization, and on the day of therapy, there is little hyperemia, easy contact bleeding, full epithelization, ulceration, mucous membrane, i.e. minimal signs of the activity of the pathological process, which corresponds to remission. Treatment discontinued. The stand of remission has come, continuing from today.
Примерз. Больной Г., 57 л,, болел хроническим неспецифическим звенным колитом в течение года. Лечилс сульфасалазином без эффекта. Поступил в период выраженной активности патологического процесса - стул 10-15 раз в сутки со слизью и кровью, интоксикаци , потер массы тела. Ректоскопи при поступлении: на прот жении 15 см (вьше осмотр невозможен из-за спазма кишки и резкой болезненности) слизиста отечна, гиперемирована , множественные эрозии. Начато ректальное введение линемента, содержащего интерферон, винилин, оливковое масло, в общеприн тых дозах . На 20-й день лечени стул 2- . 3 раза с небольщим количеством крови, интоксикаци исчезла. На 27-й день отмечена положительна динамика данных эндоскопии - началась эпителизаци эрозий. При ректороманоскопии на 30-й день лечени слизиста оболочка без признаков активности процесса (произошла эпителизаци эрозий, отеч- Hoci b, гипереми существенно уменьшились ). Лечение закончено. Наступила стойка ремисси , котора продолжаетс .Froze Patient G., 57 liters, suffered from chronic nonspecific ulcerative colitis during the year. Lechils sulfasalazine without effect. Entered in the period of pronounced activity of the pathological process - stool 10-15 times a day with mucus and blood, intoxication, loss of body weight. Rektoskopi at admission: for 15 cm (above inspection is impossible due to spasm of the intestine and severe pain) mucous swollen, hyperemic, multiple erosion. Rectal injection of liner containing interferon, vinylin, olive oil was started in conventional doses. On the 20th day of treatment, the chair 2-. 3 times with a small amount of blood, intoxication disappeared. On the 27th day, the positive dynamics of endoscopy data was noted - epithelization of erosion began. When sigmoidoscopy on the 30th day of treatment of the mucous membrane without signs of activity of the process (epithelization of erosions occurred, swelling Hoci b, hyperemia significantly decreased). The treatment is over. There is a remission stand that continues.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU843735811A SU1297865A1 (en) | 1984-05-04 | 1984-05-04 | Method of treatment of patients ill with chronic non-specific ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU843735811A SU1297865A1 (en) | 1984-05-04 | 1984-05-04 | Method of treatment of patients ill with chronic non-specific ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1297865A1 true SU1297865A1 (en) | 1987-03-23 |
Family
ID=21117091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU843735811A SU1297865A1 (en) | 1984-05-04 | 1984-05-04 | Method of treatment of patients ill with chronic non-specific ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1297865A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1842567A3 (en) * | 2001-11-08 | 2008-01-02 | Atrium Medical Corporation | Intraluminal device with a coating containing a therapeutic agent |
| US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US10864304B2 (en) | 2009-08-11 | 2020-12-15 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US10869902B2 (en) | 2004-09-28 | 2020-12-22 | Atrium Medical Corporation | Cured gel and method of making |
| US10888617B2 (en) | 2012-06-13 | 2021-01-12 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| US11083823B2 (en) | 2005-09-28 | 2021-08-10 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US11097035B2 (en) | 2010-07-16 | 2021-08-24 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
-
1984
- 1984-05-04 SU SU843735811A patent/SU1297865A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Воробьев А.И« Справочник практического врача. -.М.: Медигшна, 1981, с. 500. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1842567A3 (en) * | 2001-11-08 | 2008-01-02 | Atrium Medical Corporation | Intraluminal device with a coating containing a therapeutic agent |
| US8460693B2 (en) | 2001-11-08 | 2013-06-11 | Atrium Medical Corporation | Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent |
| US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US10869902B2 (en) | 2004-09-28 | 2020-12-22 | Atrium Medical Corporation | Cured gel and method of making |
| US11793912B2 (en) | 2004-09-28 | 2023-10-24 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US11083823B2 (en) | 2005-09-28 | 2021-08-10 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US10864304B2 (en) | 2009-08-11 | 2020-12-15 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US11097035B2 (en) | 2010-07-16 | 2021-08-24 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| US10888617B2 (en) | 2012-06-13 | 2021-01-12 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | The colitis of Behcet's disease: a separate entity? Colonoscopic findings and literature review | |
| Peters et al. | Tetracycline-induced fatty liver in nonpregnant patients: a report of six cases | |
| Lium | Etiology of ulcerative colitis: II. Effect of induced muscular spasm on colonic explants in dogs, with comment on relation of muscular spasm to ulcerative colitis | |
| SU1297865A1 (en) | Method of treatment of patients ill with chronic non-specific ulcerative colitis | |
| Logan | Chronic ulcerative colitis: a review of 117 cases | |
| WO2000016765A9 (en) | Method and composition for treatment of inflammatory bowel disease | |
| Wyatt | Prolonged symptomatic and radiological remission of colonic gas cysts after oxygen therapy | |
| KR20070065888A (en) | Use of (i) -2-cyano-3-hydroxy-but-2-enoic acid- (4'-trifluoromethylphenyl) -amide to treat inflammatory bowel disease | |
| Tripodi et al. | A case of diversion colitis treated with 5-aminosalicylic acid enemas. | |
| PT86721B (en) | A process for the preparation of a pharmaceutical composition comprising the factor XIII of human blood clotting | |
| Lumsden et al. | Intravenous Pro-Banthine in diagnostic radiology of the gastrointestinal tract with special reference to colonic disease | |
| Duffy | Reversible ischaemic colitis in young adults | |
| Coremans et al. | Migrating action potential complexes in a patient with secretory diarrhea | |
| Fuchigami et al. | Effects of total parenteral nutrition on colonic lesions in Crohn’s disease: radiographic and endoscopic study | |
| US11406659B2 (en) | Use of mannuronic diacid composition in treatment of inflammation | |
| US3996377A (en) | Medicinal preparation for treating parodontosis and method of treating parodontosis | |
| Warren et al. | Regional Enteritis: Report of Forty-Three Cases | |
| Nakajima et al. | Inhibitory action of cholecystokinin-pancreozymin on gastric pepsin secretion | |
| Zimmerman et al. | EFFECT OF ACETYLCHOLINE AND OF PHYSOSTIGMINE ON GASTRO-INTESTINAL MOTILITY: OBSERVATIONS OF NORMAL ANIMALS AND OF ANIMALS WITH EXPERIMENTAL PERITONITIS | |
| RU1790937C (en) | Method of treatment non-specific ulcerative colitis | |
| JP2025507962A (en) | GPR120 agonists for the treatment of inflammatory bowel disease - Patents.com | |
| Zhang et al. | Manifestation of Behcet's disease in the digestive tract | |
| SU1704784A1 (en) | Method for preventing acute stress peptic ulcers of the stomach and duodenum | |
| SU1319856A1 (en) | Method of treatment of postoperational enteroparesis | |
| Necheles et al. | Gastro-intestinal pathology in dogs following administration of acetylcholine and pitressin |